Literature DB >> 9290069

The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and 225-Ac in tumor-bearing mice. The ISOLDE Collaboration.

G J Beyer1, R Offord, G Künzi, Y Aleksandrova, U Ravn, S Jahn, J Barker, O Tengblad, M Lindroos.   

Abstract

High-resolution gamma spectroscopy was applied to measure simultaneously the biodistribution of carrier-free radionuclides of several lanthanides (141Ce, 145Sm, 149Gd, 167Tm) and 225Ac in tumor-bearing nude mice. Mixtures of the radiotracers were injected in solutions containing different concentrations of EDTMP (ethylenediaminetetramethylenephosphonic acid). The strong dependence of liver uptake on the ionic radius of the radio-lanthanides was confirmed for all tracers used. The ratios of radioactivity concentrated in tumour that concentrated in liver are strongly influenced by the EDTMP concentration, reaching values close to 10 for Tm, 3 for Sm, and 1 for Ac. The optimal EDTMP concentrations, giving highest tumor-to-liver ratios of enrichment, were between 1 and 10 mM for 100 microL injected volume for the animal model used in this experiment. In radionuclide therapy using EDTMP as ligands, close control of ligand concentration will be necessary.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9290069     DOI: 10.1016/s0969-8051(97)00011-5

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  8 in total

1.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

Review 2.  Actinium-225 in targeted alpha-particle therapeutic applications.

Authors:  David A Scheinberg; Michael R McDevitt
Journal:  Curr Radiopharm       Date:  2011-10

3.  A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical.

Authors:  Jaime Simón; R Keith Frank; Druce K Crump; William D Erwin; Naoto T Ueno; Richard E Wendt
Journal:  Nucl Med Biol       Date:  2012-03-28       Impact factor: 2.408

4.  Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab.

Authors:  G-J Beyer; M Miederer; S Vranjes-Durić; J J Comor; G Künzi; O Hartley; R Senekowitsch-Schmidtke; D Soloviev; F Buchegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

Review 5.  Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.

Authors:  Matthias Miederer; David A Scheinberg; Michael R McDevitt
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

6.  Production, quality control, and bio-distribution studies of (159)Gd-EDTMP as a palliative agent for bone pain.

Authors:  Simindokht Shirvani Arani; Somaye Ghasemi; Ali Bahrami Samani; Mojtaba Shamsaei Zafarghandi
Journal:  Electron Physician       Date:  2015-03-01

7.  (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.

Authors:  Ralf Bergmann; Marian Meckel; Vojtěch Kubíček; Jens Pietzsch; Jörg Steinbach; Petr Hermann; Frank Rösch
Journal:  EJNMMI Res       Date:  2016-01-16       Impact factor: 3.138

8.  PET in vivo generators 134Ce and 140Nd on an internalizing monoclonal antibody probe.

Authors:  G W Severin; J Fonslet; L K Kristensen; C H Nielsen; A I Jensen; A Kjær; A P Mazar; K Johnston; U Köster
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.